AUPC - Bauman,P.A.; Lawrence,L.A.; Biesert,L.; Dichtelmuller,H.; Fabbrizzi,F.; Gajardo,R.; Gröner,A.; Jorquera,J.I.; Kempf,C.; Kreil,T.R.; von Hoegen,I.; Pifat,D.Y.; Petteway,S.R.Jr.; Cai,K. - Critical factors influencing prion inactivation by sodium hydroxide - Vox Sanguinis 2006 Jul; 91(1): 34-40
AUHB - Burdick,M.D.; Pifat,D.Y.; Petteway,S.R.Jr.; Cai,K. - Clearance of prions during plasma protein manufacture - Transfusion Medicine Reviews 2006 Jan; 20(1): 57-62
ATSS - Cai,K.; Gierman,T.M.; Hotta,J.; Stenland,C.J.; Lee,D.C.; Pifat,D.Y.; Petteway,S.R.Jr. - Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens. - BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2005; 19(2): 79-96
ASPG - Hartwell,R.C.; Nelson,M.S.; Kislan,M.M.; Stenland,C.J.; Miller,J.L.; Pifat,D.Y.; Petteway,S.R.Jr.; Cai,K. - An improved Western blot assay to assess the clearance of prion protein from plasma-derived therapeutic proteins - Journal of Virological Methods 2005 May; 125(2): 187-93